文献速递肝病消化道肿瘤与早癌

RNA N6-甲基腺苷甲基转移酶样3通过YTHDF2依赖性转录后沉默SOCS2促进肝癌进展

RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2.
PubMed 文献 · Hepatology · 2018-04-19

研究发现在人肝细胞癌及多种实体瘤中METTL3显著上调,其过表达与肝细胞癌患者不良预后相关。敲低METTL3在体外降低肝癌细胞增殖、迁移和集落形成,在体内抑制致瘤性和肺转移;过表达METTL3则促进肝癌生长。METTL3通过m6A-YTHDF2依赖性机制降解SOCS2 mRNA,从而抑制SOCS2表达。

要点

  • METTL3在肝细胞癌中显著上调,过表达与患者不良预后相关。
  • 敲低METTL3降低肝癌细胞增殖、迁移和集落形成,并抑制体内致瘤性和肺转移。
  • METTL3通过m6A-YTHDF2依赖性途径促进SOCS2 mRNA降解,抑制SOCS2表达。

核心结论

  • METTL3在人肝细胞癌中频繁上调并促进肝癌进展。
  • METTL3通过m6A-YTHDF2依赖性机制抑制SOCS2表达,提示肝致癌过程中表观遗传改变的重要机制。

研究设计与样本

  • 采用转录组测序、m6A测序和m6A甲基化RNA免疫沉淀定量逆转录聚合酶链反应等技术,结合体外功能实验和体内成瘤及转移模型,研究METTL3在肝细胞癌中的作用。

主要发现

  • METTL3在人肝细胞癌和多种实体瘤中显著上调,其过表达与肝细胞癌患者不良预后相关。
  • 敲低METTL3在体外大幅降低肝癌细胞增殖、迁移和集落形成,在体内显著抑制肝癌致瘤性和肺转移。
  • 利用CRISPR/dCas9-VP64激活系统过表达METTL3,在体外和体内均显著促进肝癌生长。
  • 敲低METTL3大幅消除SOCS2 mRNA的m6A修饰并增加SOCS2 mRNA表达。
  • m6A介导的SOCS2 mRNA降解依赖于m6A阅读蛋白YTHDF2依赖性通路。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Epigenetic alterations have contributed greatly to human carcinogenesis. Conventional epigenetic studies have predominantly focused on DNA methylation, histone modifications, and chromatin remodeling. Recently, diverse and reversible chemical modifications of RNAs have emerged as a new layer of epigenetic regulation. N6-methyladenosine (m6A) is the most abundant chemical modification of eukaryotic messenger RNA (mRNA) and is important for the regulation of mRNA stability, splicing, and translation. Using transcriptome sequencing, we discovered that methyltransferase-like 3 (METTL3), a major RNA N6-adenosine methyltransferase, was significantly up-regulated in human hepatocellular carcinoma (HCC) and multiple solid tumors. Clinically, overexpression of METTL3 is associated with poor prognosis of patients with HCC. Functionally, we proved that knockdown of METTL3 drastically reduced HCC cell proliferation, migration, and colony formation in vitro. Knockout of METTL3 remarkably suppressed HCC tumorigenicity and lung metastasis in vivo. On the other hand, using the CRISPR/dCas9-VP64 activation system, we demonstrated that overexpression of METTL3 significantly promoted HCC growth both in vitro and in vivo. Through transcriptome sequencing, m6A sequencing, and m6A methylated RNA immuno-precipitation quantitative reverse-transcription polymerase chain reaction, we identified suppressor of cytokine signaling 2 (SOCS2) as a target of METTL3-mediated m6A modification. Knockdown of METTL3 substantially abolished SOCS2 mRNA m6A modification and augmented SOCS2 mRNA expression. We also showed that m6A-mediated SOCS2 mRNA degradation relied on the m6A reader protein YTHDF2-dependent pathway. CONCLUSION: METTL3 is frequently up-regulated in human HCC and contributes to HCC progression. METTL3 represses SOCS2 expression in HCC through an m6A-YTHDF2-dependent mechanism. Our findings suggest an important mechanism of epigenetic alteration in liver carcinogenesis. (Hepatology 2018;67:2254-2270).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Chen M, Wei L, Law CT, et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology. 2018. PMID: 29171881. doi:10.1002/hep.29683

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。